Nanose Medical

NaNose Medical enables early disease detection and staging with its cutting-edge breathomics-based technology. Uniquely designed for population-screening, it leverages nanotechnology and AI to create breath "fingerprints" from volatile biomarkers, avoiding burdensome molecules concentration analysis. Pragmatically, the portability, low-cost and ease of use make NaNose a powerful point of care population screening tool, starting with lung cancer, and liver disease screening and staging.  

We are in the clinical phase, collecting data in 5 hospitals supported by 2 grants from the EU (Horizon grant as part of LUCIA consortium and EIC Transition grant for ReLiV project.), the Israeli Innovation Authority and Google AI Fund.  

We are in a unique position to set up a strategic partnership with Pharma companies looking to accelerate drug development for lung cancer and liver diseases: The device can enable easy patient stratification, identifying eligible individuals with precision. For example, in a MASH/Fibrosis clinical study we can reduce the screen failure rate, today at ~80%, by pre-screening patients to predict their liver biopsy test result, thereby driving clinical efficiencies, saving recruitment time and reducing costs.